A closer look at “Big Pharma Accused of 'Free-Riding on Nature' as Cali Fund Raises Just $7,000”, exactly as the source publishes it. The Cali Fund, a landmark biodiversity initiative launched to raise $1 billion annually from companies that profit from nature's genetics, has received only $7,000 more than 18 months after its launch. The fund was designed to channel contributions from pharmaceutical and other industries back into conservation efforts in low-income countries, but its near-empty status has drawn sharp criticism. Campaigners and observers accuse big pharmaceutical companies of "free-riding on nature" by benefiting from genetic resources without adequately compensating the ecosystems and communities that provide them.
The fund's failure to attract substantial corporate contributions highlights a growing tension between profit-driven industries and global conservation goals. With biodiversity loss accelerating worldwide, the lack of private-sector engagement raises urgent questions about who should bear the cost of protecting nature. This listing links straight to the original page, where the content is available in full.